EverHint Signal — Momentum Swing: Pullback Standard — November 21, 2025
What This Signal Is (Quick)
The Pullback Standard setup looks for stocks that briefly dipped under their 21-day moving average (MA21), then reclaimed it with strength. This pattern often represents a healthy pause during an existing uptrend — buyers stepping back in after a controlled cooldown.
This is a pullback-style swing strategy intended for 1–4 week windows. Unlike breakout strategies, which chase strength at highs, pullback setups aim for lower-risk entries inside strong trends, using the MA21 reclaim as the trigger.
As always — this is an experimental scanner, not a recommendation engine.
How We Ranked Today (Reader Version)
Ranking used the strategy’s preferred composite score when present.
Since RSI isn’t provided in this dataset, the fallback priority becomes:
- Score
- Volume thrust
- Liquidity (adv20_dollars)
Overlays applied:
- Net Insider Flow (last 90 days)
- Days → Earnings
- Recent News Context
- Market conditions (indices, VIX, yields)
Five symbols passed the pullback criteria today.
📈 Pullback Signals — November 21, 2025
Ranked by composite score (0–1 scale → shown as 0–100)
| Rank | Ticker | Company | Sector | Last ($) | Vol Thrust | % of 52W High | Score | Market Cap | Insider Net (USD) | Days → Earnings |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EXAS | Exact Sciences Corp | Healthcare | 100.90 | 2.37x | 100% | 0 | 19.1B | -$1,300,000 | 89 |
| 2 | PODD | Insulet Corp | Healthcare | 331.17 | 1.64x | 81% | 0 | 22.0B | 0 | 62 |
| 3 | IDXX | IDEXX Laboratories | Healthcare | 725.91 | 1.58x | 95% | 0 | 94.1B | 0 | 54 |
| 4 | GAP | Gap Inc | Consumer Cyclical | 24.96 | 1.97x | 91% | 0 | 9.4B | -$1,000,000 | 83 |
| 5 | MTD | Mettler-Toledo Intl | Healthcare | 1452.35 | 1.52x | 88% | 0 | 32.2B | 0 | 97 |
Notes on Insider Net
Per the rules, only P (purchase) and S (sale) are included.
Awards, exercises, indirect ownership, and tax events are excluded.
- EXAS: multiple open-market sales → ≈ –$1.3M net selling
- GAP: isolated open-market sale → ≈ –$1.0M net selling
- Others: no qualifying purchases or sales.
Recent Headlines (Summary)
(last 7 days):
- EXAS: No fresh earnings updates, but price strength continues post prior catalysts.
- IDXX: Management commentary highlights demand resiliency in veterinary diagnostics.
- GAP: Retail sector commentary mixed; consumers cautious but holiday promotions beginning.
- PODD: Coverage notes stabilization after prior pullback in insulin delivery devices.
- MTD: Industry commentary focuses on instrumentation demand in research and biopharma.
Field Notes
A few signal characteristics worth highlighting:
Volume Thrust (1.5x+)
All five names show above-average volume, a requirement for this setup.
- EXAS shows the strongest demand (~2.37×).
- GAP also shows strong participation (~1.97×).
Price Near Highs
Pullback setups are strongest when price is close to 52-week highs after a controlled dip:
- EXAS is at 100% of its 52-week high.
- IDXX near 95%, GAP at 91%, PODD at 81%.
Sector Rotation
Healthcare dominates: 4 out of 5 names.
That aligns with broader November defensive-to-growth rotation themes seen in recent market behavior.
Vlad’s Take (EverHint)
Today’s market backdrop:
- S&P 500 +0.70%, Nasdaq +0.50%, Dow +0.97% — a broad risk-on move.
- Russell 2000 +2.72% — small caps strongly outperformed.
- VIX 23.43 (–9.87%) — volatility easing, but still in elevated territory.
- 10Y yield (^TNX) –0.05 — slightly supportive for growth.
- Crypto mixed: BTC –1.5%, ETH –2.2%.
The environment is constructive for swing trading, especially pullbacks, thanks to broad participation and improving sentiment — but elevated VIX means keeping stops modest.
Pullback Standard setups work best in steady uptrends, and today’s list fits that pattern: strong names that briefly cooled off and reclaimed trend levels. Healthcare strength is notable and aligns with market rotation into stable, high-moat businesses.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/